Literature DB >> 4403880

Combined treatment of atrial fibrillation with quinidine and beta-blockers.

G F Levi, C Proto.   

Abstract

Entities:  

Mesh:

Substances:

Year:  1972        PMID: 4403880      PMCID: PMC487020          DOI: 10.1136/hrt.34.9.911

Source DB:  PubMed          Journal:  Br Heart J        ISSN: 0007-0769


× No keyword cloud information.
  5 in total

1.  [Clinical experience with a combination of a new beta-blocking agent, LB 46, and quinidine in the treatment of chronic atrial fibrillation].

Authors:  G F Levi; C Proto
Journal:  Minerva Cardioangiol       Date:  1972-02       Impact factor: 1.347

2.  Combined treatment of atrial fibrillation with propranolol and quinidine.

Authors:  G F Levi; C Proto
Journal:  Cardiology       Date:  1970       Impact factor: 1.869

3.  [Association of LB 46-quinidine in the treatment of chronic atrial fibrillation. Electrocardiographic aspects of persons with restored sinus rhythm].

Authors:  C Proto; G P Levi; A Quadri; G F Levi
Journal:  Minerva Med       Date:  1971-07-11       Impact factor: 4.806

4.  Synthesis of some beta-adrenergic blocking agents.

Authors:  A Brändström; H Corrodi; U Junggren; T E Jönsson
Journal:  Acta Pharm Suec       Date:  1966-09

5.  Maintenance of sinus rhythm after atrial defibrillation.

Authors:  P Szekely; D A Sideris; G A Batson
Journal:  Br Heart J       Date:  1970-11
  5 in total
  3 in total

1.  Atrial fibrillation and hyperthyroidism: a new look at their relationship and therapy with lidoflazine.

Authors:  K Bruyneel; H Verhaegen; C De Vil
Journal:  Postgrad Med J       Date:  1975-01       Impact factor: 2.401

Review 2.  The pharmacologic treatment of atrial fibrillation.

Authors:  R Bolognesi
Journal:  Cardiovasc Drugs Ther       Date:  1991-06       Impact factor: 3.727

Review 3.  Clinical electrophysiologic effects of flecainide acetate.

Authors:  D Mehta; A J Camm; D E Ward
Journal:  Cardiovasc Drugs Ther       Date:  1988-03       Impact factor: 3.727

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.